Seattle Cannabis Company Capitalizes on Surging Demand
The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can't keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company's shares sky-high.
Get all the details on this potential blockbuster!

FSTX Insider Trading (F-star Therapeutics)

Insider Ownership Percentage: 2.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $9,347.94

F-star Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at F-star Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

F-star Therapeutics Share Price & Price History

Current Price: $6.65
Price Change: Price Increase of +0.55 (9.02%)
As of 10/19/2021 02:47 PM ET

This chart shows the closing price history over time for FSTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors
According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).
Show Me How This Industry Could Explode!

F-star Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/4/2021Louis KayitalireInsiderSell64$7.23$462.72View SEC Filing Icon  
7/2/2021Louis KayitalireInsiderSell1,054$8.43$8,885.22View SEC Filing Icon  
See Full Table
Insider Selling at F-star Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for F-star Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for F-star Therapeutics (NASDAQ:FSTX)

52.92% of F-star Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FSTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

F-star Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/23/2021Morgan Stanley7,868$68K0.0%+65.0%0.038%Search for SEC Filing on Google Icon
8/17/2021Price T Rowe Associates Inc. MD827,728$7.11M0.0%N/A4.274%Search for SEC Filing on Google Icon
8/17/2021Boxer Capital LLC1,751,428$15.05M0.5%N/A9.044%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC442,780$3.80M0.0%+1,159.4%2.286%Search for SEC Filing on Google Icon
8/16/2021Point72 Asset Management L.P.1,075,000$9.23M0.0%+1,333.3%5.551%Search for SEC Filing on Google Icon
8/16/2021Alyeska Investment Group L.P.150,000$1.29M0.0%N/A0.775%Search for SEC Filing on Google Icon
8/16/2021Morgan Stanley7,868$68K0.0%+65.0%0.041%Search for SEC Filing on Google Icon
8/16/2021Maven Securities LTD144,932$1.26M0.1%N/A0.748%Search for SEC Filing on Google Icon
8/16/2021State Street Corp25,070$0.22M0.0%N/A0.129%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC147,011$1.26M0.0%+6.3%0.759%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp34,452$0.30M0.0%+86.8%0.178%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC130,279$1.12M0.0%+136.9%0.673%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.773,215$6.64M0.0%+46.3%3.993%Search for SEC Filing on Google Icon
8/12/2021Dimensional Fund Advisors LP39,184$0.34M0.0%N/A0.202%Search for SEC Filing on Google Icon
8/12/2021Monashee Investment Management LLC400,000$3.44M0.4%N/A2.065%Search for SEC Filing on Google Icon
8/11/2021Bank of New York Mellon Corp45,062$0.39M0.0%N/A0.233%Search for SEC Filing on Google Icon
8/11/2021BlackRock Inc.288,750$2.48M0.0%+548.5%1.491%Search for SEC Filing on Google Icon
8/4/2021Russell Investments Group Ltd.174,773$1.50M0.0%N/A0.902%Search for SEC Filing on Google Icon
5/18/2021Point72 Asset Management L.P.75,000$0.81M0.0%N/A0.824%Search for SEC Filing on Google Icon
5/18/2021Verition Fund Management LLC128,994$1.40M0.0%N/A1.418%Search for SEC Filing on Google Icon
5/17/2021EcoR1 Capital LLC46,000$0.50M0.0%N/A0.505%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC138,311$1.50M0.0%-23.9%1.520%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp18,444$0.20M0.0%+76.5%0.203%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC55,000$0.60M0.0%+184.5%0.604%Search for SEC Filing on Google Icon
5/11/2021Acadian Asset Management LLC2,451$27K0.0%-38.7%0.027%Search for SEC Filing on Google Icon
4/23/2021BRYN MAWR TRUST Co10,000$0.11M0.0%N/A0.110%Search for SEC Filing on Google Icon
2/16/2021Endurant Capital Management LP20,445$0.20M0.1%N/A0.474%Search for SEC Filing on Google Icon
2/11/2021Arcadia Investment Management Corp MI3,000$30K0.0%N/A0.069%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC181,789$1.79M0.0%N/A4.211%Search for SEC Filing on Google Icon
2/10/2021Connolly Sarah T.53,001$0.52M0.5%N/A1.228%Search for SEC Filing on Google Icon
2/8/2021Parsons Capital Management Inc. RI23,129$0.23M0.0%N/A0.536%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.44,820$0.44M0.0%N/A1.038%Search for SEC Filing on Google Icon
2/1/2021Atlas Venture Advisors Inc.574,996$5.68M1.3%N/A13.319%Search for SEC Filing on Google Icon
1/15/2021Private Capital Advisors Inc.13,083$0.13M0.0%N/A0.303%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.
Read More on F-star Therapeutics

Today's Range

Now: $6.65
Low: $6.11
High: $6.65

50 Day Range

MA: $7.09
Low: $5.42
High: $8.24

52 Week Range

Now: $6.65
Low: $3.88
High: $15.50

Volume

609 shs

Average Volume

138,807 shs

Market Capitalization

$137.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

Who are the company insiders with the largest holdings of F-star Therapeutics?

F-star Therapeutics' top insider shareholders include:
  1. Louis Kayitalire (Insider)
Seattle Cannabis Company Capitalizes on Surging Demand
The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can't keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company's shares sky-high.
Get all the details on this potential blockbuster!